Home » Stocks » PLXP

PLx Pharma Inc. (PLXP)

Stock Price: $5.55 USD -0.21 (-3.65%)
Updated November 24, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 50.82M
Revenue (ttm) 54,323
Net Income (ttm) -10.77M
Shares Out 9.16M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $5.55
Previous Close $5.76
Change ($) -0.21
Change (%) -3.65%
Day's Open 5.91
Day's Range 5.49 - 5.98
Day's Volume 83,893
52-Week Range 1.80 - 6.42

More Stats

Market Cap 50.82M
Enterprise Value 43.28M
Earnings Date (est) Mar 19, 2021
Ex-Dividend Date n/a
Shares Outstanding 9.16M
Float 8.93M
EPS (basic) -1.22
EPS (diluted) -1.18
FCF / Share -1.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 138,574
Short Ratio 14.36
Short % of Float 1.55%
Beta 4.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 935.44
PB Ratio n/a
Revenue 54,323
Operating Income -13.52M
Net Income -10.77M
Free Cash Flow -13.56M
Net Cash 7.54M
Net Cash / Share 0.82
Gross Margin 1,040.93%
Operating Margin -24,896.81%
Profit Margin -19,833.70%
FCF Margin -24,958.26%
ROA -46.52%
ROE -226.65%
ROIC -4,837.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$9.00*
Low
9.00
Current: $5.55
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.570.750.780.02----
Revenue Growth-24.92%-3.28%3793.29%-----
Gross Profit0.570.750.780.02----
Operating Income-14.20-10.96-15.85-4.81-18.76-13.58-4.01-1.84
Net Income-20.500.90-15.35-4.91-18.74-13.58-4.01-1.84
Shares Outstanding8.928.737.024.381.180.980.58-
Earnings Per Share-3.840.10-2.19-1.12-15.92-13.84-6.96-
Operating Cash Flow-12.66-9.50-13.31-1.81-14.59-11.28-2.19-1.54
Capital Expenditures-0.23-0.65-0.54-----
Free Cash Flow-12.89-10.15-13.84-1.81-14.59-11.28-2.19-1.54
Cash & Equivalents14.0014.2524.400.0632.2127.043.861.46
Total Debt4.287.196.941.78----
Net Cash / Debt9.727.0617.46-1.7232.2127.043.861.46
Assets18.5018.3928.850.6232.4127.214.031.47
Liabilities16.9311.9424.232.941.611.260.820.16
Book Value-12.096.444.62-2.3230.8025.953.211.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PLx Pharma Inc.
Country United States
Employees 10
CEO Natasha Giordano

Stock Information

Ticker Symbol PLXP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PLXP

Description

PLx Pharma, a late-stage specialty pharmaceutical company, focuses on developing the PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce novel gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention and treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.